Among the distressing side effects of cancer treatments, hair loss is one of the most disturbing for the quality of life and adherence to therapy in breast cancer patients. Many patients take nutritional supplements to prevent hair loss or enhance regrowth. Based on their mechanism and timing of use, nutritional supplements could be divided into safe, cautious, debated, and contraindicated categories. Non-contraindicated supplements generally include safe supplements like vitamin D, which is not known to interfere with cancer treatments. Those that are contraindicated include phytoestrogens and compounds affecting estrogen pathways because of the risk of stimulating tumor growth in cancers sensitive to estrogen. Antioxidants like tocotrienols and resveratrol are given judiciously because of potential interference with cancer therapies dependent on reactive oxygen species. Supplements debated, including nicotinamide, folate, and iron, pose a risk by promoting cellular proliferation or altering the tumor microenvironment. Biotin is nontoxic but interferes with blood test results and is thus difficult in cancer monitoring. Evidence regarding nutritional supplements’ safety and efficacy in this context is conflicting. Management by an oncologist is required along with more studies to clearly establish the safety parameters and efficacy guidelines.

Sechi, A., Cedirian, S., Brunetti, T., Quadrelli, F., Torres, F., Tosti, A., et al. (2025). Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients. NUTRIENTS, 17(9), 1-16 [10.3390/nu17091451].

Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients

Cedirian, Stephano;Brunetti, Tullio
;
Quadrelli, Federico;
2025

Abstract

Among the distressing side effects of cancer treatments, hair loss is one of the most disturbing for the quality of life and adherence to therapy in breast cancer patients. Many patients take nutritional supplements to prevent hair loss or enhance regrowth. Based on their mechanism and timing of use, nutritional supplements could be divided into safe, cautious, debated, and contraindicated categories. Non-contraindicated supplements generally include safe supplements like vitamin D, which is not known to interfere with cancer treatments. Those that are contraindicated include phytoestrogens and compounds affecting estrogen pathways because of the risk of stimulating tumor growth in cancers sensitive to estrogen. Antioxidants like tocotrienols and resveratrol are given judiciously because of potential interference with cancer therapies dependent on reactive oxygen species. Supplements debated, including nicotinamide, folate, and iron, pose a risk by promoting cellular proliferation or altering the tumor microenvironment. Biotin is nontoxic but interferes with blood test results and is thus difficult in cancer monitoring. Evidence regarding nutritional supplements’ safety and efficacy in this context is conflicting. Management by an oncologist is required along with more studies to clearly establish the safety parameters and efficacy guidelines.
2025
Sechi, A., Cedirian, S., Brunetti, T., Quadrelli, F., Torres, F., Tosti, A., et al. (2025). Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients. NUTRIENTS, 17(9), 1-16 [10.3390/nu17091451].
Sechi, Andrea; Cedirian, Stephano; Brunetti, Tullio; Quadrelli, Federico; Torres, Fernanda; Tosti, Antonella; Rinaldi, Fabio; Pinto, Daniela; Bolognin...espandi
File in questo prodotto:
File Dimensione Formato  
nutrients-17-01451.pdf

accesso aperto

Tipo: Versione (PDF) editoriale / Version Of Record
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 295.41 kB
Formato Adobe PDF
295.41 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1072737
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
  • OpenAlex ND
social impact